Related Experiment Video
Updated: Mar 26, 2026

A Standardized Procedure of Dressing Management for Toxic Epidermal Necrolysis
Published on: March 14, 2025
New therapeutic options for skin and soft tissue infections
Matteo Bassetti1, Elda Righi, Alessia Carnelutti
1Infectious Diseases Division, Santa Maria Misericordia Hospital, Udine, Italy.
Purpose Of Review:
The occurrence of methicillin-resistance in Staphylococcus aureus, that represents the most frequent cause of complicated skin and soft tissue infections (cSSTIs) worldwide, is a major concern and has been associated with increased length of stay, health care costs, and overall mortality. Although vancomycin is still considered the standard therapy in this setting, limitations of its use in clinical practice are represented by a progressive increase in methicillin-resistant S. aureus (MRSA) minimum inhibitory concentrations, drug-related toxicity, and the lack of an oral formulation. New therapeutic options for MRSA cSSTIs have recently become available, with promising implications for the management of cSSTIs in clinical practice.
Recent Findings:
A number of new antimicrobials with activity against MRSA have been recently approved for the treatment of cSSTIs, and other agents are under investigation. We have reviewed the recent developments, with a specific focus on the possible advantages of new drugs for the management of cSSTIs into the everyday clinical practice.
Summary:
The new approved drugs for the treatment of cSSTIs are expected to offer many advantages for the management of patients with suspected or confirmed MRSA cSSTIs. The most promising features of the new compounds include the availability of oral formulations, once-weekly intravenous regimens, and broad spectra of activity.
Insights
New antibiotics are emerging for methicillin-resistant Staphylococcus aureus (MRSA) complicated skin and soft tissue infections (cSSTIs). These novel treatments offer oral options and convenient dosing, improving patient management.
Area of Science:
- Infectious Diseases
- Microbiology
- Pharmacology
Background:
- Methicillin-resistant Staphylococcus aureus (MRSA) is a leading cause of complicated skin and soft tissue infections (cSSTIs) globally.
- Vancomycin, the current standard, faces challenges including rising resistance, toxicity, and lack of oral options.
- MRSA cSSTIs are linked to prolonged hospital stays, increased costs, and higher mortality rates.
Purpose of the Study:
- To review recent advancements in antimicrobial therapies for MRSA cSSTIs.
- To evaluate the potential benefits of new drugs in clinical practice.
- To highlight emerging treatment options for healthcare providers.
Main Methods:
- Literature review of recent developments in antimicrobial agents for MRSA cSSTIs.
- Focus on approved and investigational drugs with activity against MRSA.
- Analysis of drug characteristics relevant to clinical application.
Main Results:
- Several new antimicrobials active against MRSA have been approved for cSSTI treatment.
- Ongoing research is exploring additional therapeutic agents.
- New drugs demonstrate promising features for managing MRSA cSSTIs.
Conclusions:
- Newly approved drugs offer significant advantages for MRSA cSSTI management.
- Key benefits include oral formulations and once-weekly IV regimens.
- Broad-spectrum activity is another promising characteristic of these novel compounds.
Related Concept Videos
Staphylococcal Skin Infections
Skin Diseases and Disorders
Gram-positive Staphylococcus spp. and Streptococcus spp. are responsible for many of the most common skin infections. However, many...
Acne Infection
Hand hygiene
Hand washing...
Inflammatory Bowel Disease IV: Pharmacological Management
Pharmacologic...
Endocarditis III: Medical Management

